Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study
Roughly 70–80% of patients with advanced stage Hodgkin's lymphoma are cured with various first-line and second-line treatments, including ABVD, BEACOPP, and stem-cell transplantation. Brentuximab vedotin has shown significant clinical activity, with a manageable safety profile, in patients with...
Gespeichert in:
| Veröffentlicht in: | The lancet oncology Jg. 14; H. 13; S. 1348 - 1356 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
England
Elsevier Ltd
01.12.2013
Elsevier Limited |
| Schlagworte: | |
| ISSN: | 1470-2045, 1474-5488, 1474-5488 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Roughly 70–80% of patients with advanced stage Hodgkin's lymphoma are cured with various first-line and second-line treatments, including ABVD, BEACOPP, and stem-cell transplantation. Brentuximab vedotin has shown significant clinical activity, with a manageable safety profile, in patients with relapsed or refractory Hodgkin's lymphoma. We aimed to assess the safety and early clinical efficacy of this drug as first-line treatment in combination with standard or modified-standard treatment in patients with previously untreated Hodgkin's lymphoma.
We did a phase 1, open-label, dose-escalation safety study comparing brentuximab vedotin in combination with standard (ABVD) or a modified-standard (AVD) treatment. Patients were enrolled into the groups sequentially. Main entry criteria were newly diagnosed, treatment-naive, CD30-positive patients with Hodgkin's lymphoma who had histologically confirmed stage IIA bulky disease or stage IIB–IV disease and an Eastern Cooperative Oncology Group performance status of two or less. Patients received doses of 0·6, 0·9, or 1·2 mg/kg brentuximab vedotin by intravenous infusion every 2 weeks with either ABVD (25 mg/m2 doxorubicin, 10 units/m2 bleomycin, 6 mg/m2 vinblastine, and 375 mg/m2 dacarbazine) or AVD (ABVD modified regimen without the inclusion of bleomycin) for up to six cycles. Our primary objectives were to assess the safety profile and establish the maximum tolerated dose (MTD) of brentuximab vedotin in combination with ABVD and AVD. The safety profile and MTD was assessed for the safety population. The study has completed and the final analysis is presented. This study was registered with ClinicalTrials.gov, number NCT01060904.
Between Jan 29, 2010, and Sept 17, 2012, 51 patients were enrolled and received at least one dose of brentuximab vedotin. The maximum tolerated dose of brentuximab vedotin when combined with ABVD or AVD was not exceeded at 1·2 mg/kg. 21 (95%) of 22 patients given brentuximab vedotin and ABVD achieved complete remission, as did 24 (96%) of 25 patients given brentuximab vedotin and AVD. Adverse events were generally grade 1 or 2; however, an unacceptable number of patients in the brentuximab vedotin and ABVD groups had pulmonary toxic effects (11 [44%] of 25), which exceeded the historical incidence for ABVD alone. No patients experienced pulmonary toxic effects when treated with brentuximab vedotin plus AVD. The most common grade 3 or worse events were neutropenia (20 [80%] of 25 patients in the brentuximab vedotin and ABVD group vs 20 [77%] of 26 patients in the brentuximab vedotin and AVD group), anaemia (five [20%] vs three [12%]), febrile neutropenia (five [20%] vs two [8%]), pulmonary toxic effects (six [24%] vs 0), syncope (three [12%] vs two [8%]), dyspnoea (three [12%] vs one [4%]), pulmonary embolism (three [12%] vs 0), fatigue (one [4%] each), and leucopenia (one [4%] each). Serious events occured in 41% of all patients (14 [56%] in the brentuximab vedotin and ABVD group and seven [27%] in the brentuximab vedotin and AVD group). Serious events occurring in 10% of patients or more overall were febrile neutropenia (four [16%] in the brentuximab vedotin and ABVD group vs two [8%] in the brentuximab vedotin and AVD group), and, in the brentuximab vedotin and ABVD group only, pulmonary toxic effects (six [24%]).
Brentuximab vedotin should not be given with bleomycin in general or specifically as first-line therapy for patients with treatment naive, advanced stage Hodgkin's lymphoma. 1·2 mg/kg brentuximab vedotin combined with AVD given every 2 weeks was generally well tolerated by patients. At present, a phase 3 trial comparing brentuximab vedotin plus AVD to ABVD alone is ongoing (ClinicalTrials.gov, number NCT01712490) and will formally assess whether brentuximab vedotin plus AVD might redefine therapy in treatment-naive patients with Hodgkin's lymphoma.
Seattle Genetics Inc and Takeda Pharmaceuticals International Co. |
|---|---|
| AbstractList | Roughly 70–80% of patients with advanced stage Hodgkin's lymphoma are cured with various first-line and second-line treatments, including ABVD, BEACOPP, and stem-cell transplantation. Brentuximab vedotin has shown significant clinical activity, with a manageable safety profile, in patients with relapsed or refractory Hodgkin's lymphoma. We aimed to assess the safety and early clinical efficacy of this drug as first-line treatment in combination with standard or modified-standard treatment in patients with previously untreated Hodgkin's lymphoma.
We did a phase 1, open-label, dose-escalation safety study comparing brentuximab vedotin in combination with standard (ABVD) or a modified-standard (AVD) treatment. Patients were enrolled into the groups sequentially. Main entry criteria were newly diagnosed, treatment-naive, CD30-positive patients with Hodgkin's lymphoma who had histologically confirmed stage IIA bulky disease or stage IIB–IV disease and an Eastern Cooperative Oncology Group performance status of two or less. Patients received doses of 0·6, 0·9, or 1·2 mg/kg brentuximab vedotin by intravenous infusion every 2 weeks with either ABVD (25 mg/m2 doxorubicin, 10 units/m2 bleomycin, 6 mg/m2 vinblastine, and 375 mg/m2 dacarbazine) or AVD (ABVD modified regimen without the inclusion of bleomycin) for up to six cycles. Our primary objectives were to assess the safety profile and establish the maximum tolerated dose (MTD) of brentuximab vedotin in combination with ABVD and AVD. The safety profile and MTD was assessed for the safety population. The study has completed and the final analysis is presented. This study was registered with ClinicalTrials.gov, number NCT01060904.
Between Jan 29, 2010, and Sept 17, 2012, 51 patients were enrolled and received at least one dose of brentuximab vedotin. The maximum tolerated dose of brentuximab vedotin when combined with ABVD or AVD was not exceeded at 1·2 mg/kg. 21 (95%) of 22 patients given brentuximab vedotin and ABVD achieved complete remission, as did 24 (96%) of 25 patients given brentuximab vedotin and AVD. Adverse events were generally grade 1 or 2; however, an unacceptable number of patients in the brentuximab vedotin and ABVD groups had pulmonary toxic effects (11 [44%] of 25), which exceeded the historical incidence for ABVD alone. No patients experienced pulmonary toxic effects when treated with brentuximab vedotin plus AVD. The most common grade 3 or worse events were neutropenia (20 [80%] of 25 patients in the brentuximab vedotin and ABVD group vs 20 [77%] of 26 patients in the brentuximab vedotin and AVD group), anaemia (five [20%] vs three [12%]), febrile neutropenia (five [20%] vs two [8%]), pulmonary toxic effects (six [24%] vs 0), syncope (three [12%] vs two [8%]), dyspnoea (three [12%] vs one [4%]), pulmonary embolism (three [12%] vs 0), fatigue (one [4%] each), and leucopenia (one [4%] each). Serious events occured in 41% of all patients (14 [56%] in the brentuximab vedotin and ABVD group and seven [27%] in the brentuximab vedotin and AVD group). Serious events occurring in 10% of patients or more overall were febrile neutropenia (four [16%] in the brentuximab vedotin and ABVD group vs two [8%] in the brentuximab vedotin and AVD group), and, in the brentuximab vedotin and ABVD group only, pulmonary toxic effects (six [24%]).
Brentuximab vedotin should not be given with bleomycin in general or specifically as first-line therapy for patients with treatment naive, advanced stage Hodgkin's lymphoma. 1·2 mg/kg brentuximab vedotin combined with AVD given every 2 weeks was generally well tolerated by patients. At present, a phase 3 trial comparing brentuximab vedotin plus AVD to ABVD alone is ongoing (ClinicalTrials.gov, number NCT01712490) and will formally assess whether brentuximab vedotin plus AVD might redefine therapy in treatment-naive patients with Hodgkin's lymphoma.
Seattle Genetics Inc and Takeda Pharmaceuticals International Co. Roughly 70-80% of patients with advanced stage Hodgkin's lymphoma are cured with various first-line and second-line treatments, including ABVD, BEACOPP, and stem-cell transplantation. Brentuximab vedotin has shown significant clinical activity, with a manageable safety profile, in patients with relapsed or refractory Hodgkin's lymphoma. We aimed to assess the safety and early clinical efficacy of this drug as first-line treatment in combination with standard or modified-standard treatment in patients with previously untreated Hodgkin's lymphoma. We did a phase 1, open-label, dose-escalation safety study comparing brentuximab vedotin in combination with standard (ABVD) or a modified-standard (AVD) treatment. Patients were enrolled into the groups sequentially. Main entry criteria were newly diagnosed, treatment-naive, CD30-positive patients with Hodgkin's lymphoma who had histologically confirmed stage IIA bulky disease or stage IIB-IV disease and an Eastern Cooperative Oncology Group performance status of two or less. Patients received doses of 0·6, 0·9, or 1·2 mg/kg brentuximab vedotin by intravenous infusion every 2 weeks with either ABVD (25 mg/m(2) doxorubicin, 10 units/m(2) bleomycin, 6 mg/m(2) vinblastine, and 375 mg/m(2) dacarbazine) or AVD (ABVD modified regimen without the inclusion of bleomycin) for up to six cycles. Our primary objectives were to assess the safety profile and establish the maximum tolerated dose (MTD) of brentuximab vedotin in combination with ABVD and AVD. The safety profile and MTD was assessed for the safety population. The study has completed and the final analysis is presented. This study was registered with ClinicalTrials.gov, number NCT01060904. Between Jan 29, 2010, and Sept 17, 2012, 51 patients were enrolled and received at least one dose of brentuximab vedotin. The maximum tolerated dose of brentuximab vedotin when combined with ABVD or AVD was not exceeded at 1·2 mg/kg. 21 (95%) of 22 patients given brentuximab vedotin and ABVD achieved complete remission, as did 24 (96%) of 25 patients given brentuximab vedotin and AVD. Adverse events were generally grade 1 or 2; however, an unacceptable number of patients in the brentuximab vedotin and ABVD groups had pulmonary toxic effects (11 [44%] of 25), which exceeded the historical incidence for ABVD alone. No patients experienced pulmonary toxic effects when treated with brentuximab vedotin plus AVD. The most common grade 3 or worse events were neutropenia (20 [80%] of 25 patients in the brentuximab vedotin and ABVD group vs 20 [77%] of 26 patients in the brentuximab vedotin and AVD group), anaemia (five [20%] vs three [12%]), febrile neutropenia (five [20%] vs two [8%]), pulmonary toxic effects (six [24%] vs 0), syncope (three [12%] vs two [8%]), dyspnoea (three [12%] vs one [4%]), pulmonary embolism (three [12%] vs 0), fatigue (one [4%] each), and leucopenia (one [4%] each). Serious events occured in 41% of all patients (14 [56%] in the brentuximab vedotin and ABVD group and seven [27%] in the brentuximab vedotin and AVD group). Serious events occurring in 10% of patients or more overall were febrile neutropenia (four [16%] in the brentuximab vedotin and ABVD group vs two [8%] in the brentuximab vedotin and AVD group), and, in the brentuximab vedotin and ABVD group only, pulmonary toxic effects (six [24%]). Brentuximab vedotin should not be given with bleomycin in general or specifically as first-line therapy for patients with treatment naive, advanced stage Hodgkin's lymphoma. 1·2 mg/kg brentuximab vedotin combined with AVD given every 2 weeks was generally well tolerated by patients. At present, a phase 3 trial comparing brentuximab vedotin plus AVD to ABVD alone is ongoing (ClinicalTrials.gov, number NCT01712490) and will formally assess whether brentuximab vedotin plus AVD might redefine therapy in treatment-naive patients with Hodgkin's lymphoma. Seattle Genetics Inc and Takeda Pharmaceuticals International Co. Roughly 70-80% of patients with advanced stage Hodgkin's lymphoma are cured with various first-line and second-line treatments, including ABVD, BEACOPP, and stem-cell transplantation. Brentuximab vedotin has shown significant clinical activity, with a manageable safety profile, in patients with relapsed or refractory Hodgkin's lymphoma. We aimed to assess the safety and early clinical efficacy of this drug as first-line treatment in combination with standard or modified-standard treatment in patients with previously untreated Hodgkin's lymphoma.BACKGROUNDRoughly 70-80% of patients with advanced stage Hodgkin's lymphoma are cured with various first-line and second-line treatments, including ABVD, BEACOPP, and stem-cell transplantation. Brentuximab vedotin has shown significant clinical activity, with a manageable safety profile, in patients with relapsed or refractory Hodgkin's lymphoma. We aimed to assess the safety and early clinical efficacy of this drug as first-line treatment in combination with standard or modified-standard treatment in patients with previously untreated Hodgkin's lymphoma.We did a phase 1, open-label, dose-escalation safety study comparing brentuximab vedotin in combination with standard (ABVD) or a modified-standard (AVD) treatment. Patients were enrolled into the groups sequentially. Main entry criteria were newly diagnosed, treatment-naive, CD30-positive patients with Hodgkin's lymphoma who had histologically confirmed stage IIA bulky disease or stage IIB-IV disease and an Eastern Cooperative Oncology Group performance status of two or less. Patients received doses of 0·6, 0·9, or 1·2 mg/kg brentuximab vedotin by intravenous infusion every 2 weeks with either ABVD (25 mg/m(2) doxorubicin, 10 units/m(2) bleomycin, 6 mg/m(2) vinblastine, and 375 mg/m(2) dacarbazine) or AVD (ABVD modified regimen without the inclusion of bleomycin) for up to six cycles. Our primary objectives were to assess the safety profile and establish the maximum tolerated dose (MTD) of brentuximab vedotin in combination with ABVD and AVD. The safety profile and MTD was assessed for the safety population. The study has completed and the final analysis is presented. This study was registered with ClinicalTrials.gov, number NCT01060904.METHODSWe did a phase 1, open-label, dose-escalation safety study comparing brentuximab vedotin in combination with standard (ABVD) or a modified-standard (AVD) treatment. Patients were enrolled into the groups sequentially. Main entry criteria were newly diagnosed, treatment-naive, CD30-positive patients with Hodgkin's lymphoma who had histologically confirmed stage IIA bulky disease or stage IIB-IV disease and an Eastern Cooperative Oncology Group performance status of two or less. Patients received doses of 0·6, 0·9, or 1·2 mg/kg brentuximab vedotin by intravenous infusion every 2 weeks with either ABVD (25 mg/m(2) doxorubicin, 10 units/m(2) bleomycin, 6 mg/m(2) vinblastine, and 375 mg/m(2) dacarbazine) or AVD (ABVD modified regimen without the inclusion of bleomycin) for up to six cycles. Our primary objectives were to assess the safety profile and establish the maximum tolerated dose (MTD) of brentuximab vedotin in combination with ABVD and AVD. The safety profile and MTD was assessed for the safety population. The study has completed and the final analysis is presented. This study was registered with ClinicalTrials.gov, number NCT01060904.Between Jan 29, 2010, and Sept 17, 2012, 51 patients were enrolled and received at least one dose of brentuximab vedotin. The maximum tolerated dose of brentuximab vedotin when combined with ABVD or AVD was not exceeded at 1·2 mg/kg. 21 (95%) of 22 patients given brentuximab vedotin and ABVD achieved complete remission, as did 24 (96%) of 25 patients given brentuximab vedotin and AVD. Adverse events were generally grade 1 or 2; however, an unacceptable number of patients in the brentuximab vedotin and ABVD groups had pulmonary toxic effects (11 [44%] of 25), which exceeded the historical incidence for ABVD alone. No patients experienced pulmonary toxic effects when treated with brentuximab vedotin plus AVD. The most common grade 3 or worse events were neutropenia (20 [80%] of 25 patients in the brentuximab vedotin and ABVD group vs 20 [77%] of 26 patients in the brentuximab vedotin and AVD group), anaemia (five [20%] vs three [12%]), febrile neutropenia (five [20%] vs two [8%]), pulmonary toxic effects (six [24%] vs 0), syncope (three [12%] vs two [8%]), dyspnoea (three [12%] vs one [4%]), pulmonary embolism (three [12%] vs 0), fatigue (one [4%] each), and leucopenia (one [4%] each). Serious events occured in 41% of all patients (14 [56%] in the brentuximab vedotin and ABVD group and seven [27%] in the brentuximab vedotin and AVD group). Serious events occurring in 10% of patients or more overall were febrile neutropenia (four [16%] in the brentuximab vedotin and ABVD group vs two [8%] in the brentuximab vedotin and AVD group), and, in the brentuximab vedotin and ABVD group only, pulmonary toxic effects (six [24%]).FINDINGSBetween Jan 29, 2010, and Sept 17, 2012, 51 patients were enrolled and received at least one dose of brentuximab vedotin. The maximum tolerated dose of brentuximab vedotin when combined with ABVD or AVD was not exceeded at 1·2 mg/kg. 21 (95%) of 22 patients given brentuximab vedotin and ABVD achieved complete remission, as did 24 (96%) of 25 patients given brentuximab vedotin and AVD. Adverse events were generally grade 1 or 2; however, an unacceptable number of patients in the brentuximab vedotin and ABVD groups had pulmonary toxic effects (11 [44%] of 25), which exceeded the historical incidence for ABVD alone. No patients experienced pulmonary toxic effects when treated with brentuximab vedotin plus AVD. The most common grade 3 or worse events were neutropenia (20 [80%] of 25 patients in the brentuximab vedotin and ABVD group vs 20 [77%] of 26 patients in the brentuximab vedotin and AVD group), anaemia (five [20%] vs three [12%]), febrile neutropenia (five [20%] vs two [8%]), pulmonary toxic effects (six [24%] vs 0), syncope (three [12%] vs two [8%]), dyspnoea (three [12%] vs one [4%]), pulmonary embolism (three [12%] vs 0), fatigue (one [4%] each), and leucopenia (one [4%] each). Serious events occured in 41% of all patients (14 [56%] in the brentuximab vedotin and ABVD group and seven [27%] in the brentuximab vedotin and AVD group). Serious events occurring in 10% of patients or more overall were febrile neutropenia (four [16%] in the brentuximab vedotin and ABVD group vs two [8%] in the brentuximab vedotin and AVD group), and, in the brentuximab vedotin and ABVD group only, pulmonary toxic effects (six [24%]).Brentuximab vedotin should not be given with bleomycin in general or specifically as first-line therapy for patients with treatment naive, advanced stage Hodgkin's lymphoma. 1·2 mg/kg brentuximab vedotin combined with AVD given every 2 weeks was generally well tolerated by patients. At present, a phase 3 trial comparing brentuximab vedotin plus AVD to ABVD alone is ongoing (ClinicalTrials.gov, number NCT01712490) and will formally assess whether brentuximab vedotin plus AVD might redefine therapy in treatment-naive patients with Hodgkin's lymphoma.INTERPRETATIONBrentuximab vedotin should not be given with bleomycin in general or specifically as first-line therapy for patients with treatment naive, advanced stage Hodgkin's lymphoma. 1·2 mg/kg brentuximab vedotin combined with AVD given every 2 weeks was generally well tolerated by patients. At present, a phase 3 trial comparing brentuximab vedotin plus AVD to ABVD alone is ongoing (ClinicalTrials.gov, number NCT01712490) and will formally assess whether brentuximab vedotin plus AVD might redefine therapy in treatment-naive patients with Hodgkin's lymphoma.Seattle Genetics Inc and Takeda Pharmaceuticals International Co.FUNDINGSeattle Genetics Inc and Takeda Pharmaceuticals International Co. Summary Background: Roughly 70-80% of patients with advanced stage Hodgkin's lymphoma are cured with various first-line and second-line treatments, including ABVD, BEACOPP, and stem-cell transplantation. Brentuximab vedotin has shown significant clinical activity, with a manageable safety profile, in patients with relapsed or refractory Hodgkin's lymphoma. We aimed to assess the safety and early clinical efficacy of this drug as first-line treatment in combination with standard or modified-standard treatment in patients with previously untreated Hodgkin's lymphoma. Methods: We did a phase 1, open-label, dose-escalation safety study comparing brentuximab vedotin in combination with standard (ABVD) or a modified-standard (AVD) treatment. Patients were enrolled into the groups sequentially. Main entry criteria were newly diagnosed, treatment-naive, CD30-positive patients with Hodgkin's lymphoma who had histologically confirmed stage IIA bulky disease or stage IIB-IV disease and an Eastern Cooperative Oncology Group performance status of two or less. Patients received doses of 0.6, 0.9, or 1.2 mg/kg brentuximab vedotin by intravenous infusion every 2 weeks with either ABVD (25 mg/m2 doxorubicin, 10 units/m2 bleomycin, 6 mg/m2 vinblastine, and 375 mg/m2 dacarbazine) or AVD (ABVD modified regimen without the inclusion of bleomycin) for up to six cycles. Our primary objectives were to assess the safety profile and establish the maximum tolerated dose (MTD) of brentuximab vedotin in combination with ABVD and AVD. The safety profile and MTD was assessed for the safety population. The study has completed and the final analysis is presented. This study was registered with ClinicalTrials.gov, number NCT01060904. Findings: Between Jan 29, 2010, and Sept 17, 2012, 51 patients were enrolled and received at least one dose of brentuximab vedotin. The maximum tolerated dose of brentuximab vedotin when combined with ABVD or AVD was not exceeded at 1.2 mg/kg. 21 (95%) of 22 patients given brentuximab vedotin and ABVD achieved complete remission, as did 24 (96%) of 25 patients given brentuximab vedotin and AVD. Adverse events were generally grade 1 or 2; however, an unacceptable number of patients in the brentuximab vedotin and ABVD groups had pulmonary toxic effects (11 [44%] of 25), which exceeded the historical incidence for ABVD alone. No patients experienced pulmonary toxic effects when treated with brentuximab vedotin plus AVD. The most common grade 3 or worse events were neutropenia (20 [80%] of 25 patients in the brentuximab vedotin and ABVD group vs 20 [77%] of 26 patients in the brentuximab vedotin and AVD group), anaemia (five [20%] vs three [12%]), febrile neutropenia (five [20%] vs two [8%]), pulmonary toxic effects (six [24%] vs 0), syncope (three [12%] vs two [8%]), dyspnoea (three [12%] vs one [4%]), pulmonary embolism (three [12%] vs 0), fatigue (one [4%] each), and leucopenia (one [4%] each). Serious events occured in 41% of all patients (14 [56%] in the brentuximab vedotin and ABVD group and seven [27%] in the brentuximab vedotin and AVD group). Serious events occurring in 10% of patients or more overall were febrile neutropenia (four [16%] in the brentuximab vedotin and ABVD group vs two [8%] in the brentuximab vedotin and AVD group), and, in the brentuximab vedotin and ABVD group only, pulmonary toxic effects (six [24%]). Interpretation: Brentuximab vedotin should not be given with bleomycin in general or specifically as first-line therapy for patients with treatment naive, advanced stage Hodgkin's lymphoma. 1.2 mg/kg brentuximab vedotin combined with AVD given every 2 weeks was generally well tolerated by patients. At present, a phase 3 trial comparing brentuximab vedotin plus AVD to ABVD alone is ongoing (ClinicalTrials.gov, number NCT01712490) and will formally assess whether brentuximab vedotin plus AVD might redefine therapy in treatment-naive patients with Hodgkin's lymphoma. Funding Seattle Genetics Inc and Takeda Pharmaceuticals International Co. Background Roughly 70-80% of patients with advanced stage Hodgkin's lymphoma are cured with various first-line and second-line treatments, including ABVD, BEACOPP, and stem-cell transplantation. Brentuximab vedotin has shown significant clinical activity, with a manageable safety profile, in patients with relapsed or refractory Hodgkin's lymphoma. We aimed to assess the safety and early clinical efficacy of this drug as first-line treatment in combination with standard or modified-standard treatment in patients with previously untreated Hodgkin's lymphoma. Methods We did a phase 1, open-label, dose-escalation safety study comparing brentuximab vedotin in combination with standard (ABVD) or a modified-standard (AVD) treatment. Patients were enrolled into the groups sequentially. Main entry criteria were newly diagnosed, treatment-naive, CD30-positive patients with Hodgkin's lymphoma who had histologically confirmed stage IIA bulky disease or stage IIB-IV disease and an Eastern Cooperative Oncology Group performance status of two or less. Patients received doses of 0 times 6, 0 times 9, or 1 times 2 mg/kg brentuximab vedotin by intravenous infusion every 2 weeks with either ABVD (25 mg/m2 doxorubicin, 10 units/m2 bleomycin, 6 mg/m2 vinblastine, and 375 mg/m2 dacarbazine) or AVD (ABVD modified regimen without the inclusion of bleomycin) for up to six cycles. Our primary objectives were to assess the safety profile and establish the maximum tolerated dose (MTD) of brentuximab vedotin in combination with ABVD and AVD. The safety profile and MTD was assessed for the safety population. The study has completed and the final analysis is presented. This study was registered with ClinicalTrials.gov, number NCT01060904. Findings Between Jan 29, 2010, and Sept 17, 2012, 51 patients were enrolled and received at least one dose of brentuximab vedotin. The maximum tolerated dose of brentuximab vedotin when combined with ABVD or AVD was not exceeded at 1 times 2 mg/kg. 21 (95%) of 22 patients given brentuximab vedotin and ABVD achieved complete remission, as did 24 (96%) of 25 patients given brentuximab vedotin and AVD. Adverse events were generally grade 1 or 2; however, an unacceptable number of patients in the brentuximab vedotin and ABVD groups had pulmonary toxic effects (11 [44%] of 25), which exceeded the historical incidence for ABVD alone. No patients experienced pulmonary toxic effects when treated with brentuximab vedotin plus AVD. The most common grade 3 or worse events were neutropenia (20 [80%] of 25 patients in the brentuximab vedotin and ABVD group 20 [77%] of 26 patients in the brentuximab vedotin and AVD group), anaemia (five [20%] three [12%]), febrile neutropenia (five [20%] two [8%]), pulmonary toxic effects (six [24%] 0), syncope (three [12%] two [8%]), dyspnoea (three [12%] one [4%]), pulmonary embolism (three [12%] 0), fatigue (one [4%] each), and leucopenia (one [4%] each). Serious events occured in 41% of all patients (14 [56%] in the brentuximab vedotin and ABVD group and seven [27%] in the brentuximab vedotin and AVD group). Serious events occurring in 10% of patients or more overall were febrile neutropenia (four [16%] in the brentuximab vedotin and ABVD group two [8%] in the brentuximab vedotin and AVD group), and, in the brentuximab vedotin and ABVD group only, pulmonary toxic effects (six [24%]). Interpretation Brentuximab vedotin should not be given with bleomycin in general or specifically as first-line therapy for patients with treatment naive, advanced stage Hodgkin's lymphoma. 1 times 2 mg/kg brentuximab vedotin combined with AVD given every 2 weeks was generally well tolerated by patients. At present, a phase 3 trial comparing brentuximab vedotin plus AVD to ABVD alone is ongoing (ClinicalTrials.gov, number NCT01712490) and will formally assess whether brentuximab vedotin plus AVD might redefine therapy in treatment-naive patients with Hodgkin's lymphoma. Funding Seattle Genetics Inc and Takeda Pharmaceuticals International Co. Summary Background Roughly 70–80% of patients with advanced stage Hodgkin's lymphoma are cured with various first-line and second-line treatments, including ABVD, BEACOPP, and stem-cell transplantation. Brentuximab vedotin has shown significant clinical activity, with a manageable safety profile, in patients with relapsed or refractory Hodgkin's lymphoma. We aimed to assess the safety and early clinical efficacy of this drug as first-line treatment in combination with standard or modified-standard treatment in patients with previously untreated Hodgkin's lymphoma. Methods We did a phase 1, open-label, dose-escalation safety study comparing brentuximab vedotin in combination with standard (ABVD) or a modified-standard (AVD) treatment. Patients were enrolled into the groups sequentially. Main entry criteria were newly diagnosed, treatment-naive, CD30-positive patients with Hodgkin's lymphoma who had histologically confirmed stage IIA bulky disease or stage IIB–IV disease and an Eastern Cooperative Oncology Group performance status of two or less. Patients received doses of 0·6, 0·9, or 1·2 mg/kg brentuximab vedotin by intravenous infusion every 2 weeks with either ABVD (25 mg/m2 doxorubicin, 10 units/m2 bleomycin, 6 mg/m2 vinblastine, and 375 mg/m2 dacarbazine) or AVD (ABVD modified regimen without the inclusion of bleomycin) for up to six cycles. Our primary objectives were to assess the safety profile and establish the maximum tolerated dose (MTD) of brentuximab vedotin in combination with ABVD and AVD. The safety profile and MTD was assessed for the safety population. The study has completed and the final analysis is presented. This study was registered with ClinicalTrials.gov , number NCT01060904. Findings Between Jan 29, 2010, and Sept 17, 2012, 51 patients were enrolled and received at least one dose of brentuximab vedotin. The maximum tolerated dose of brentuximab vedotin when combined with ABVD or AVD was not exceeded at 1·2 mg/kg. 21 (95%) of 22 patients given brentuximab vedotin and ABVD achieved complete remission, as did 24 (96%) of 25 patients given brentuximab vedotin and AVD. Adverse events were generally grade 1 or 2; however, an unacceptable number of patients in the brentuximab vedotin and ABVD groups had pulmonary toxic effects (11 [44%] of 25), which exceeded the historical incidence for ABVD alone. No patients experienced pulmonary toxic effects when treated with brentuximab vedotin plus AVD. The most common grade 3 or worse events were neutropenia (20 [80%] of 25 patients in the brentuximab vedotin and ABVD group vs 20 [77%] of 26 patients in the brentuximab vedotin and AVD group), anaemia (five [20%] vs three [12%]), febrile neutropenia (five [20%] vs two [8%]), pulmonary toxic effects (six [24%] vs 0), syncope (three [12%] vs two [8%]), dyspnoea (three [12%] vs one [4%]), pulmonary embolism (three [12%] vs 0), fatigue (one [4%] each), and leucopenia (one [4%] each). Serious events occured in 41% of all patients (14 [56%] in the brentuximab vedotin and ABVD group and seven [27%] in the brentuximab vedotin and AVD group). Serious events occurring in 10% of patients or more overall were febrile neutropenia (four [16%] in the brentuximab vedotin and ABVD group vs two [8%] in the brentuximab vedotin and AVD group), and, in the brentuximab vedotin and ABVD group only, pulmonary toxic effects (six [24%]). Interpretation Brentuximab vedotin should not be given with bleomycin in general or specifically as first-line therapy for patients with treatment naive, advanced stage Hodgkin's lymphoma. 1·2 mg/kg brentuximab vedotin combined with AVD given every 2 weeks was generally well tolerated by patients. At present, a phase 3 trial comparing brentuximab vedotin plus AVD to ABVD alone is ongoing ( ClinicalTrials.gov , number NCT01712490 ) and will formally assess whether brentuximab vedotin plus AVD might redefine therapy in treatment-naive patients with Hodgkin's lymphoma. Funding Seattle Genetics Inc and Takeda Pharmaceuticals International Co. Roughly 70-80% of patients with advanced stage Hodgkin's lymphoma are cured with various first-line and second-line treatments, including ABVD, BEACOPP, and stem-cell transplantation. Brentuximab vedotin has shown significant clinical activity, with a manageable safety profile, in patients with relapsed or refractory Hodgkin's lymphoma. We aimed to assess the safety and early clinical efficacy of this drug as first-line treatment in combination with standard or modified-standard treatment in patients with previously untreated Hodgkin's lymphoma. Methods We did a phase 1, open-label, dose-escalation safety study comparing brentuximab vedotin in combination with standard (ABVD) or a modified-standard (AVD) treatment. Patients were enrolled into the groups sequentially. Main entry criteria were newly diagnosed, treatment-naive, CD30-positive patients with Hodgkin's lymphoma who had histologically confirmed stage IIA bulky disease or stage IIB-IV disease and an Eastern Cooperative Oncology Group performance status of two or less. Patients received doses of 0·6, 0·9, or 1·2 mg/kg brentuximab vedotin by intravenous infusion every 2 weeks with either ABVD (25 mg/m2doxorubicin, 10 units/m2bleomycin, 6 mg/m2vinblastine, and 375 mg/m2dacarbazine) or AVD (ABVD modified regimen without the inclusion of bleomycin) for up to six cycles. Our primary objectives were to assess the safety profile and establish the maximum tolerated dose (MTD) of brentuximab vedotin in combination with ABVD and AVD. The safety profile and MTD was assessed for the safety population. The study has completed and the final analysis is presented. This study was registered withClinicalTrials.gov, numberNCT01060904. Findings Between Jan 29, 2010, and Sept 17, 2012, 51 patients were enrolled and received at least one dose of brentuximab vedotin. The maximum tolerated dose of brentuximab vedotin when combined with ABVD or AVD was not exceeded at 1·2 mg/kg. 21 (95%) of 22 patients given brentuximab vedotin and ABVD achieved complete remission, as did 24 (96%) of 25 patients given brentuximab vedotin and AVD. Adverse events were generally grade 1 or 2; however, an unacceptable number of patients in the brentuximab vedotin and ABVD groups had pulmonary toxic effects (11 [44%] of 25), which exceeded the historical incidence for ABVD alone. No patients experienced pulmonary toxic effects when treated with brentuximab vedotin plus AVD. The most common grade 3 or worse events were neutropenia (20 [80%] of 25 patients in the brentuximab vedotin and ABVD groupvs20 [77%] of 26 patients in the brentuximab vedotin and AVD group), anaemia (five [20%]vsthree [12%]), febrile neutropenia (five [20%]vstwo [8%]), pulmonary toxic effects (six [24%]vs0), syncope (three [12%]vstwo [8%]), dyspnoea (three [12%]vsone [4%]), pulmonary embolism (three [12%]vs0), fatigue (one [4%] each), and leucopenia (one [4%] each). Serious events occured in 41% of all patients (14 [56%] in the brentuximab vedotin and ABVD group and seven [27%] in the brentuximab vedotin and AVD group). Serious events occurring in 10% of patients or more overall were febrile neutropenia (four [16%] in the brentuximab vedotin and ABVD groupvstwo [8%] in the brentuximab vedotin and AVD group), and, in the brentuximab vedotin and ABVD group only, pulmonary toxic effects (six [24%]). Interpretation Brentuximab vedotin should not be given with bleomycin in general or specifically as first-line therapy for patients with treatment naive, advanced stage Hodgkin's lymphoma. 1·2 mg/kg brentuximab vedotin combined with AVD given every 2 weeks was generally well tolerated by patients. At present, a phase 3 trial comparing brentuximab vedotin plus AVD to ABVD alone is ongoing (ClinicalTrials.gov, numberNCT01712490) and will formally assess whether brentuximab vedotin plus AVD might redefine therapy in treatment-naive patients with Hodgkin's lymphoma. Funding Seattle Genetics Inc and Takeda Pharmaceuticals International Co. |
| Author | Park, Steven I Hunder, Naomi N Ansell, Stephen M O'Meara, Megan M Huebner, Dirk Connors, Joseph M Younes, Anas Fanale, Michelle |
| Author_xml | – sequence: 1 givenname: Anas surname: Younes fullname: Younes, Anas email: younesa@mskcc.org organization: University of Texas MD Anderson Cancer Center, Houston, TX, USA – sequence: 2 givenname: Joseph M surname: Connors fullname: Connors, Joseph M organization: BC Cancer Agency Centre for Lymphoid Cancer, Vancouver, BC, Canada – sequence: 3 givenname: Steven I surname: Park fullname: Park, Steven I organization: University of North Carolina at Chapel Hill, Chapel Hill, NC, USA – sequence: 4 givenname: Michelle surname: Fanale fullname: Fanale, Michelle organization: University of Texas MD Anderson Cancer Center, Houston, TX, USA – sequence: 5 givenname: Megan M surname: O'Meara fullname: O'Meara, Megan M organization: Seattle Genetics Inc, Bothell, WA, USA – sequence: 6 givenname: Naomi N surname: Hunder fullname: Hunder, Naomi N organization: Seattle Genetics Inc, Bothell, WA, USA – sequence: 7 givenname: Dirk surname: Huebner fullname: Huebner, Dirk organization: Takeda Pharmaceuticals International Co, Cambridge, MA, USA – sequence: 8 givenname: Stephen M surname: Ansell fullname: Ansell, Stephen M organization: Mayo Clinic, Rochester, MN, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/24239220$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkttu1DAURSNURC_wCSBLPFCkBmzHjpMiQNNyKVIlHri8Wh77pOM2sUOctOQv-GScSQFpJDR9OlGy9pKds_eTHecdJMljgl8QTPKXXwgTOKWY8UOSPReYY5KSe8lefM1SzopiZ_08I7vJfgiXGBNBMH-Q7FJGs5JSvJf8OunA9cNP26glugbje-uQ9s3SOjDoxvYrtDj5_g75Di3iqOJsVW9jJsxfHdzUIzJWXTgfYuTMm4sr654FVI9Nu_KNOkYKtSsVAJEj5Ftwaa2WUB8hEwMpBK3qaPQOhX4w48PkfqXqAI9u50Hy7cP7r6dn6fnnj59OF-ep5nnRpwwrUXJNMBTYaFA6Y4IbzQ2oXFSaUFLlRckUz4BXwohcFLwqOWbLQmtdldlBcjh7287_GCD0srFBQ10rB34IkghOKBVFRu-GkoyUZDvKckqKArM8ok830Es_dC7eeaJYyTNOcaSe3FLDsgEj2y5uqhvlnw1GgM-A7nwIHVR_EYLl1BS5boqcaiBJJtdNkdNJX23ktO3Xe-g7Zeut6bdzGuKKri10MuhYCg3GdqB7abzdanizYdC1dTaW4QpGCP_-hQxU4lkyOUi2NkyC1_8X3OEAvwEFLP12 |
| CODEN | LANCAO |
| CitedBy_id | crossref_primary_10_1016_j_critrevonc_2020_102897 crossref_primary_10_1111_bjh_15789 crossref_primary_10_1002_ajh_24184 crossref_primary_10_1200_JCO_2017_75_2543 crossref_primary_10_1136_jitc_2021_004445 crossref_primary_10_1080_10428194_2019_1663419 crossref_primary_10_3390_ph13090245 crossref_primary_10_1002_chem_202101805 crossref_primary_10_1080_10428194_2017_1300898 crossref_primary_10_1002_ajh_24226 crossref_primary_10_1016_j_bmcl_2018_10_043 crossref_primary_10_1097_HS9_0000000000000052 crossref_primary_10_1080_10428194_2020_1731497 crossref_primary_10_1080_17474086_2017_1270202 crossref_primary_10_12688_f1000research_8301_1 crossref_primary_10_1080_17474086_2017_1350167 crossref_primary_10_3389_fonc_2022_948513 crossref_primary_10_1182_blood_2017_09_772640 crossref_primary_10_1080_17474086_2019_1558399 crossref_primary_10_1111_bjh_13803 crossref_primary_10_1158_1078_0432_CCR_21_2023 crossref_primary_10_1080_10428194_2019_1608529 crossref_primary_10_1007_s11899_016_0345_y crossref_primary_10_1016_j_ccell_2016_04_001 crossref_primary_10_1016_j_heliyon_2023_e21776 crossref_primary_10_1007_s00520_018_4523_4 crossref_primary_10_1177_1078155218800150 crossref_primary_10_2745_dds_32_126 crossref_primary_10_1007_s11864_017_0460_6 crossref_primary_10_1002_phar_1687 crossref_primary_10_1097_MPH_0000000000002301 crossref_primary_10_1016_S1470_2045_13_70528_X crossref_primary_10_1182_blood_2014_08_551598 crossref_primary_10_1200_JCO_2015_62_4817 crossref_primary_10_1016_S1470_2045_18_30426_1 crossref_primary_10_1182_blood_2020009806 crossref_primary_10_1007_s12254_015_0230_8 crossref_primary_10_1016_j_bulcan_2016_10_011 crossref_primary_10_1093_jjco_hyu204 crossref_primary_10_1586_17474086_2015_1044432 crossref_primary_10_1080_17474086_2020_1793666 crossref_primary_10_3390_cancers11081071 crossref_primary_10_1080_0284186X_2018_1426877 crossref_primary_10_1007_s00277_017_3157_9 crossref_primary_10_1200_EDBK_200359 crossref_primary_10_1038_s41408_021_00518_z crossref_primary_10_1053_j_seminhematol_2016_05_006 crossref_primary_10_3389_fcell_2020_576391 crossref_primary_10_1517_14728214_2014_912277 crossref_primary_10_1016_j_mayocp_2015_07_005 crossref_primary_10_1586_17474086_2015_995622 crossref_primary_10_1186_s41687_023_00653_0 crossref_primary_10_1182_blood_2014_05_577627 crossref_primary_10_1007_s00228_023_03557_6 crossref_primary_10_1016_j_critrevonc_2019_03_016 crossref_primary_10_1053_j_seminhematol_2016_05_001 crossref_primary_10_1182_blood_2017_06_787200 crossref_primary_10_1002_ajh_23750 crossref_primary_10_1053_j_seminoncol_2014_08_001 crossref_primary_10_1097_CCO_0000000000000310 crossref_primary_10_1111_ejh_12396 crossref_primary_10_1007_s15004_019_6592_z crossref_primary_10_1016_j_canlet_2014_03_030 crossref_primary_10_3322_caac_21438 crossref_primary_10_3389_frhem_2023_1171991 crossref_primary_10_1007_s40272_017_0265_x crossref_primary_10_1002_cpt_1530 crossref_primary_10_1002_ajh_24272 crossref_primary_10_1007_s11899_015_0262_5 crossref_primary_10_1038_s41573_023_00709_2 crossref_primary_10_1007_s11912_015_0466_9 crossref_primary_10_1002_smtd_202401783 crossref_primary_10_1111_bjh_13578 crossref_primary_10_1053_j_seminhematol_2016_05_011 crossref_primary_10_1056_NEJMe1604026 crossref_primary_10_1200_EDBK_159036 crossref_primary_10_1038_nrclinonc_2017_128 crossref_primary_10_1080_14740338_2016_1179277 crossref_primary_10_5858_arpa_2021_0338_RA crossref_primary_10_1136_bcr_2018_227676 crossref_primary_10_1080_10428194_2016_1277387 crossref_primary_10_1002_pbc_26278 crossref_primary_10_1002_pbc_25621 crossref_primary_10_1016_j_bulcan_2017_11_008 crossref_primary_10_1080_17474086_2017_1313701 crossref_primary_10_1007_s11912_019_0788_0 crossref_primary_10_1016_j_critrevonc_2015_08_014 crossref_primary_10_1097_COC_0000000000000294 crossref_primary_10_1111_bjh_15586 crossref_primary_10_1002_ajh_25071 crossref_primary_10_1080_17474086_2023_2276212 crossref_primary_10_1158_1078_0432_CCR_17_3021 crossref_primary_10_1111_bjh_15622 crossref_primary_10_1182_blood_2014_06_537514 crossref_primary_10_1517_14656566_2014_909411 crossref_primary_10_1517_14740338_2015_1084285 crossref_primary_10_1097_QAD_0000000000001729 crossref_primary_10_2217_ijh_15_27 crossref_primary_10_1155_2015_428169 crossref_primary_10_1007_s00277_017_3226_0 crossref_primary_10_1111_imj_13051 crossref_primary_10_1111_ejh_13269 crossref_primary_10_3389_fonc_2022_1006166 crossref_primary_10_1182_blood_2017_05_784678 crossref_primary_10_1182_blood_2017_08_798553 crossref_primary_10_1016_j_pcl_2014_09_010 crossref_primary_10_1177_2040620715625615 crossref_primary_10_1016_S0140_6736_17_32134_7 crossref_primary_10_1016_S1470_2045_18_30510_2 crossref_primary_10_1016_j_bmc_2020_115783 crossref_primary_10_1080_17474086_2019_1658522 crossref_primary_10_14338_IJPT_18_00040_1 crossref_primary_10_1093_annonc_mdu189 crossref_primary_10_1111_bjh_12862 crossref_primary_10_1111_joim_12582 crossref_primary_10_1002_hon_2838 crossref_primary_10_1056_NEJMoa1708984 crossref_primary_10_2217_fon_14_248 crossref_primary_10_1517_14712598_2015_1130821 crossref_primary_10_3390_ph8030607 crossref_primary_10_1002_ajh_26717 crossref_primary_10_1097_MJT_0000000000000145 crossref_primary_10_1007_s11864_015_0360_6 crossref_primary_10_1038_s41375_019_0545_2 crossref_primary_10_1517_17425255_2015_1007950 crossref_primary_10_2217_fon_2020_0026 crossref_primary_10_1182_bloodadvances_2020001871 crossref_primary_10_1080_14728214_2017_1366447 crossref_primary_10_1186_s13045_018_0601_9 crossref_primary_10_1007_s11899_018_0485_3 crossref_primary_10_1093_rheumatology_keae235 crossref_primary_10_1016_j_bbmt_2015_04_022 crossref_primary_10_1007_s00277_018_3366_x crossref_primary_10_1007_s12185_016_2007_1 crossref_primary_10_1016_j_critrevonc_2023_103923 crossref_primary_10_1002_ajh_27470 crossref_primary_10_1002_ange_201608292 crossref_primary_10_1016_j_clml_2015_06_008 crossref_primary_10_1111_bjh_15566 crossref_primary_10_3390_medicina60081272 crossref_primary_10_1002_ajh_25856 crossref_primary_10_3390_pharmaceutics17091164 crossref_primary_10_1111_bjh_14078 crossref_primary_10_1007_s11899_014_0215_4 crossref_primary_10_1182_blood_2016_03_703470 crossref_primary_10_1182_blood_2019001272 crossref_primary_10_1016_S1470_2045_17_30696_4 crossref_primary_10_14694_EdBook_AM_2015_35_e479 crossref_primary_10_7759_cureus_41660 crossref_primary_10_1080_17474086_2016_1205949 crossref_primary_10_1097_CCO_0000000000000079 crossref_primary_10_5301_tj_5000608 crossref_primary_10_1016_j_pop_2016_07_012 crossref_primary_10_7759_cureus_23993 crossref_primary_10_1016_j_blre_2022_100949 crossref_primary_10_1159_000500222 crossref_primary_10_1200_JCO_18_00122 crossref_primary_10_1159_000479224 crossref_primary_10_1177_2040620718786833 crossref_primary_10_3390_ph9020028 crossref_primary_10_1080_17474086_2016_1235970 crossref_primary_10_3109_08880018_2015_1071903 crossref_primary_10_1093_annonc_mdv256 crossref_primary_10_1016_j_esmogo_2025_100154 crossref_primary_10_1517_13543784_2014_908184 crossref_primary_10_1002_anie_201608292 crossref_primary_10_1111_ejh_12347 crossref_primary_10_1186_s13256_018_1693_0 crossref_primary_10_1188_18_CJON_E103_E114 crossref_primary_10_1016_j_ctarc_2024_100806 crossref_primary_10_1007_s11864_014_0275_7 crossref_primary_10_1080_10428194_2020_1791846 crossref_primary_10_1111_bjh_13372 crossref_primary_10_1182_blood_2014_09_551556 crossref_primary_10_1097_PPO_0000000000000168 crossref_primary_10_1177_2040620717695723 crossref_primary_10_1016_j_ijrobp_2017_12_005 crossref_primary_10_1016_j_clml_2015_02_006 crossref_primary_10_1016_j_pharmthera_2020_107552 crossref_primary_10_1016_S2352_3026_21_00129_0 crossref_primary_10_1200_JCO_2014_59_4853 crossref_primary_10_1586_17474086_2015_1081562 crossref_primary_10_1080_10428194_2016_1185789 crossref_primary_10_2147_OTT_S193951 crossref_primary_10_3923_ijp_2017_785_807 |
| Cites_doi | 10.1200/JCO.2012.43.4803 10.1200/JCO.2007.11.6525 10.1016/S0140-6736(11)61940-5 10.1200/JCO.2011.38.0410 10.1007/s00259-010-1490-5 10.1200/JCO.2003.12.086 10.7326/0003-4819-77-6-861 10.1200/JCO.2009.23.3239 10.1016/0140-6736(93)92411-L 10.1200/JCO.2005.02.7243 10.1200/JCO.2005.05.016 10.1200/JCO.2006.09.2403 10.3324/haematol.2011.045856 10.1200/JCO.2008.17.0910 10.1200/JCO.2005.02.907 10.1200/JCO.2007.11.9867 10.2967/jnumed.112.110890 10.1016/S0140-6736(02)08938-9 10.1182/blood-2006-04-019901 10.1056/NEJMoa1100340 10.1200/JCO.2004.99.010 |
| ContentType | Journal Article |
| Copyright | 2013 Elsevier Ltd Elsevier Ltd Copyright © 2013 Elsevier Ltd. All rights reserved. Copyright Elsevier Limited Jan 2013 |
| Copyright_xml | – notice: 2013 Elsevier Ltd – notice: Elsevier Ltd – notice: Copyright © 2013 Elsevier Ltd. All rights reserved. – notice: Copyright Elsevier Limited Jan 2013 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7RV 7TO 7X7 7XB 88E 8AO 8C1 8C2 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH H94 K9. KB0 M0S M1P NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 |
| DOI | 10.1016/S1470-2045(13)70501-1 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Nursing & Allied Health Database Oncogenes and Growth Factors Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Lancet Titles Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Health & Medical Collection Medical Database Nursing & Allied Health Premium Proquest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) Lancet Titles ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Public Health ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic Oncogenes and Growth Factors Abstracts Oncogenes and Growth Factors Abstracts Oncogenes and Growth Factors Abstracts |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7RV name: Nursing & Allied Health Database url: https://search.proquest.com/nahs sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1474-5488 |
| EndPage | 1356 |
| ExternalDocumentID | 3146030591 24239220 10_1016_S1470_2045_13_70501_1 S1470204513705011 1_s2_0_S1470204513705011 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Clinical Trial, Phase I |
| GeographicLocations | United States--US |
| GeographicLocations_xml | – name: United States--US |
| GrantInformation | Seattle Genetics Inc and Takeda Pharmaceuticals International Co. |
| GroupedDBID | --- --K --M -RU .1- .55 .FO 0R~ 123 1B1 1P~ 1~5 29L 4.4 457 4CK 4G. 53G 5VS 6PF 7-5 71M 7RV 7X7 88E 8AO 8C1 8C2 8FI 8FJ AAEDT AAEDW AAIKJ AAKOC AALRI AAMRU AAQFI AAQQT AAQXK AATTM AAWTL AAXKI AAXUO AAYWO ABBQC ABMAC ABMZM ABUWG ABWVN ACGFS ACIEU ACLOT ACPRK ACRLP ACRPL ACVFH ADBBV ADCNI ADMUD ADNMO AEIPS AEKER AENEX AEUPX AEVXI AFKRA AFPUW AFRHN AFTJW AFXIZ AGHFR AGQPQ AHMBA AIGII AIIUN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BENPR BKEYQ BKOJK BNPGV BPHCQ BVXVI CCPQU CS3 DU5 EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 EX3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN FYUFA G-Q GBLVA HMCUK HVGLF HZ~ IHE J1W KOM M1P M41 MO0 N9A NAPCQ O-L O9- OC~ OO- OZT P-8 P-9 P2P PCD PHGZM PHGZT PJZUB PPXIY PQQKQ PROAC PSQYO R2- ROL RPZ SDG SEL SES SPCBC SSH SSZ T5K TLN UKHRP UV1 WOW X7M XBR Z5R ~HD 3V. AACTN AFCTW AFKWA AJOXV ALIPV AMFUW RIG SDF ABLVK ABYKQ AHPSJ AJBFU ZA5 9DU AAYXX AFFHD CITATION AGCQF AGRNS CGR CUY CVF ECM EIF NPM 7TO 7XB 8FK H94 K9. PKEHL PQEST PQUKI PRINS 7X8 PUEGO |
| ID | FETCH-LOGICAL-c568t-40a795c10e80dceac3475dc5dea67fc121f6894a53e5f7d76785f9504b8cccf93 |
| IEDL.DBID | 7RV |
| ISICitedReferencesCount | 227 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000327539600047&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1470-2045 1474-5488 |
| IngestDate | Sun Sep 28 05:28:17 EDT 2025 Sun Nov 09 10:04:43 EST 2025 Sun Nov 09 12:19:24 EST 2025 Tue Oct 07 05:28:53 EDT 2025 Mon Jul 21 06:02:46 EDT 2025 Sat Nov 29 07:03:19 EST 2025 Tue Nov 18 22:33:24 EST 2025 Fri Feb 23 02:29:54 EST 2024 Sun Feb 23 10:18:52 EST 2025 Tue Oct 14 19:38:59 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 13 |
| Language | English |
| License | Copyright © 2013 Elsevier Ltd. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c568t-40a795c10e80dceac3475dc5dea67fc121f6894a53e5f7d76785f9504b8cccf93 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| PMID | 24239220 |
| PQID | 1464953520 |
| PQPubID | 23462 |
| PageCount | 9 |
| ParticipantIDs | proquest_miscellaneous_1751227832 proquest_miscellaneous_1751213191 proquest_miscellaneous_1462188046 proquest_journals_1464953520 pubmed_primary_24239220 crossref_primary_10_1016_S1470_2045_13_70501_1 crossref_citationtrail_10_1016_S1470_2045_13_70501_1 elsevier_sciencedirect_doi_10_1016_S1470_2045_13_70501_1 elsevier_clinicalkeyesjournals_1_s2_0_S1470204513705011 elsevier_clinicalkey_doi_10_1016_S1470_2045_13_70501_1 |
| PublicationCentury | 2000 |
| PublicationDate | 2013-12-01 |
| PublicationDateYYYYMMDD | 2013-12-01 |
| PublicationDate_xml | – month: 12 year: 2013 text: 2013-12-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | The lancet oncology |
| PublicationTitleAlternate | Lancet Oncol |
| PublicationYear | 2013 |
| Publisher | Elsevier Ltd Elsevier Limited |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier Limited |
| References | Dann, Bar-Shalom, Tamir (bib23) 2007; 109 Younes, Gopal, Smith (bib11) 2012; 30 Linch, Winfield, Goldstone (bib21) 1993; 341 Martin, Ristow, Habermann, Colgan, Witzig, Ansell (bib16) 2005; 23 Advani, Maeda, Lavori (bib19) 2007; 25 McEarchern, Kennedy, McCormick (bib12) 2010; 95 Schmitz, Pfistner, Sextro (bib20) 2002; 359 Cheson, Pfistner, Juweid (bib13) 2007; 25 Barrington, Qian, Somer (bib14) 2010; 37 Yagoda, Mukherji, Young (bib8) 1972; 77 Gordon, Hong, Fisher (bib4) 2013; 31 bib22 Viviani, Zinzani, Rambaldi (bib7) 2011; 365 Biggi, Gallamini, Chauvie (bib15) 2013; 54 Hoskin, Lowry, Horwich (bib10) 2009; 27 Harel, Ferme, Poirot (bib1) 2011; 96 Engert, Haverkamp, Kobe (bib6) 2012; 379 Borchmann, Diehl, Goergen (bib24) 2010; 95 Gobbi, Levis, Chisesi (bib18) 2005; 23 Gallamini, Hutchings, Rigacci (bib3) 2007; 25 Connors (bib2) 2005; 23 Federico, Luminari, Iannitto (bib5) 2009; 27 Duggan, Petroni, Johnson (bib9) 2003; 21 Canellos, Duggan, Johnson, Niedzwiecki (bib17) 2004; 22 Duggan (10.1016/S1470-2045(13)70501-1_bib9) 2003; 21 Gobbi (10.1016/S1470-2045(13)70501-1_bib18) 2005; 23 Viviani (10.1016/S1470-2045(13)70501-1_bib7) 2011; 365 Biggi (10.1016/S1470-2045(13)70501-1_bib15) 2013; 54 Gallamini (10.1016/S1470-2045(13)70501-1_bib3) 2007; 25 Cheson (10.1016/S1470-2045(13)70501-1_bib13) 2007; 25 Barrington (10.1016/S1470-2045(13)70501-1_bib14) 2010; 37 Yagoda (10.1016/S1470-2045(13)70501-1_bib8) 1972; 77 Martin (10.1016/S1470-2045(13)70501-1_bib16) 2005; 23 Hoskin (10.1016/S1470-2045(13)70501-1_bib10) 2009; 27 Advani (10.1016/S1470-2045(13)70501-1_bib19) 2007; 25 McEarchern (10.1016/S1470-2045(13)70501-1_bib12) 2010; 95 Connors (10.1016/S1470-2045(13)70501-1_bib2) 2005; 23 Federico (10.1016/S1470-2045(13)70501-1_bib5) 2009; 27 Engert (10.1016/S1470-2045(13)70501-1_bib6) 2012; 379 Younes (10.1016/S1470-2045(13)70501-1_bib11) 2012; 30 Gordon (10.1016/S1470-2045(13)70501-1_bib4) 2013; 31 Schmitz (10.1016/S1470-2045(13)70501-1_bib20) 2002; 359 Harel (10.1016/S1470-2045(13)70501-1_bib1) 2011; 96 Canellos (10.1016/S1470-2045(13)70501-1_bib17) 2004; 22 Dann (10.1016/S1470-2045(13)70501-1_bib23) 2007; 109 Linch (10.1016/S1470-2045(13)70501-1_bib21) 1993; 341 Borchmann (10.1016/S1470-2045(13)70501-1_bib24) 2010; 95 24815777 - Immunotherapy. 2014;6(4):371-5 24239219 - Lancet Oncol. 2013 Dec;14(13):1254-6 |
| References_xml | – volume: 25 start-page: 3902 year: 2007 end-page: 3907 ident: bib19 article-title: Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin's Disease publication-title: J Clin Oncol – volume: 23 start-page: 6400 year: 2005 end-page: 6408 ident: bib2 article-title: State-of-the-art therapeutics: Hodgkin's lymphoma publication-title: J Clin Oncol – volume: 31 start-page: 684 year: 2013 end-page: 691 ident: bib4 article-title: Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496) publication-title: J Clin Oncol – volume: 54 start-page: 683 year: 2013 end-page: 690 ident: bib15 article-title: International validation study for interim PET in ABVD-treated, advanced-stage Hodgkin lymphoma: interpretation criteria and concordance rate among reviewers publication-title: J Nucl Med – volume: 25 start-page: 3746 year: 2007 end-page: 3752 ident: bib3 article-title: Early interim 2-[ publication-title: J Clin Oncol – volume: 22 start-page: 1532 year: 2004 end-page: 1533 ident: bib17 article-title: How important is bleomycin in the adriamycin + bleomycin + vinblastine + dacarbazine regimen? publication-title: J Clin Oncol – volume: 95 year: 2010 ident: bib24 article-title: Dacarbazine is an essential component of ABVD in the treatment of early favourable Hodgkin lymphoma: results of the second interim analysis of the GHSG HD13 trial publication-title: Haematologica – volume: 21 start-page: 607 year: 2003 end-page: 614 ident: bib9 article-title: Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial publication-title: J Clin Oncol – volume: 23 start-page: 9198 year: 2005 end-page: 9207 ident: bib18 article-title: ABVD versus modified Stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi publication-title: J Clin Oncol – volume: 25 start-page: 579 year: 2007 end-page: 586 ident: bib13 article-title: Revised response criteria for malignant lymphoma publication-title: J Clin Oncol – volume: 379 start-page: 1791 year: 2012 end-page: 1799 ident: bib6 article-title: Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial publication-title: Lancet – volume: 27 start-page: 5390 year: 2009 end-page: 5396 ident: bib10 article-title: Randomized comparison of the Stanford V regimen and ABVD in the treatment of advanced Hodgkin's lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244 publication-title: J Clin Oncol – volume: 341 start-page: 1051 year: 1993 end-page: 1054 ident: bib21 article-title: Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial publication-title: Lancet – volume: 96 start-page: 1692 year: 2011 end-page: 1699 ident: bib1 article-title: Management of fertility in patients treated for Hodgkin's lymphoma publication-title: Haematologica – volume: 365 start-page: 203 year: 2011 end-page: 212 ident: bib7 article-title: ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned publication-title: N Engl J Med – volume: 30 start-page: 2183 year: 2012 end-page: 2189 ident: bib11 article-title: Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma publication-title: J Clin Oncol – volume: 37 start-page: 1824 year: 2010 end-page: 1833 ident: bib14 article-title: Concordance between four European centres of PET reporting criteria designed for use in multicenter trials in Hodgkin lymphoma publication-title: Eur J Nucl Med – volume: 77 start-page: 861 year: 1972 end-page: 870 ident: bib8 article-title: Bleomycin, an antitumor antibiotic. Clinical experience in 274 patients publication-title: Ann Intern Med – volume: 95 year: 2010 ident: bib12 article-title: Activity of SGN-35 in preclinical models of combination therapy and relapse prevention publication-title: Haematologica – ident: bib22 article-title: Clinical practice guidelines in oncology: Hodgkin lymphoma v 2.2013 – volume: 27 start-page: 805 year: 2009 end-page: 811 ident: bib5 article-title: ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial publication-title: J Clin Oncol – volume: 109 start-page: 905 year: 2007 end-page: 909 ident: bib23 article-title: Risk adapted BEACOPP regimen can reduce the cumulative dose chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome publication-title: Blood – volume: 359 start-page: 2065 year: 2002 end-page: 2071 ident: bib20 article-title: Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial publication-title: Lancet – volume: 23 start-page: 7614 year: 2005 end-page: 7620 ident: bib16 article-title: Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma publication-title: J Clin Oncol – volume: 31 start-page: 684 year: 2013 ident: 10.1016/S1470-2045(13)70501-1_bib4 article-title: Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496) publication-title: J Clin Oncol doi: 10.1200/JCO.2012.43.4803 – volume: 25 start-page: 3746 year: 2007 ident: 10.1016/S1470-2045(13)70501-1_bib3 article-title: Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to International Prognostic Score in advanced-stage Hodgkin's lymphoma: a report form a joint Italian-Danish study publication-title: J Clin Oncol doi: 10.1200/JCO.2007.11.6525 – volume: 379 start-page: 1791 year: 2012 ident: 10.1016/S1470-2045(13)70501-1_bib6 article-title: Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial publication-title: Lancet doi: 10.1016/S0140-6736(11)61940-5 – volume: 95 issue: suppl year: 2010 ident: 10.1016/S1470-2045(13)70501-1_bib12 article-title: Activity of SGN-35 in preclinical models of combination therapy and relapse prevention publication-title: Haematologica – volume: 95 issue: suppl year: 2010 ident: 10.1016/S1470-2045(13)70501-1_bib24 article-title: Dacarbazine is an essential component of ABVD in the treatment of early favourable Hodgkin lymphoma: results of the second interim analysis of the GHSG HD13 trial publication-title: Haematologica – volume: 30 start-page: 2183 year: 2012 ident: 10.1016/S1470-2045(13)70501-1_bib11 article-title: Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma publication-title: J Clin Oncol doi: 10.1200/JCO.2011.38.0410 – volume: 37 start-page: 1824 year: 2010 ident: 10.1016/S1470-2045(13)70501-1_bib14 article-title: Concordance between four European centres of PET reporting criteria designed for use in multicenter trials in Hodgkin lymphoma publication-title: Eur J Nucl Med doi: 10.1007/s00259-010-1490-5 – volume: 21 start-page: 607 year: 2003 ident: 10.1016/S1470-2045(13)70501-1_bib9 article-title: Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial publication-title: J Clin Oncol doi: 10.1200/JCO.2003.12.086 – volume: 77 start-page: 861 year: 1972 ident: 10.1016/S1470-2045(13)70501-1_bib8 article-title: Bleomycin, an antitumor antibiotic. Clinical experience in 274 patients publication-title: Ann Intern Med doi: 10.7326/0003-4819-77-6-861 – volume: 27 start-page: 5390 year: 2009 ident: 10.1016/S1470-2045(13)70501-1_bib10 article-title: Randomized comparison of the Stanford V regimen and ABVD in the treatment of advanced Hodgkin's lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244 publication-title: J Clin Oncol doi: 10.1200/JCO.2009.23.3239 – volume: 341 start-page: 1051 year: 1993 ident: 10.1016/S1470-2045(13)70501-1_bib21 article-title: Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial publication-title: Lancet doi: 10.1016/0140-6736(93)92411-L – volume: 23 start-page: 7614 year: 2005 ident: 10.1016/S1470-2045(13)70501-1_bib16 article-title: Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma publication-title: J Clin Oncol doi: 10.1200/JCO.2005.02.7243 – volume: 23 start-page: 6400 year: 2005 ident: 10.1016/S1470-2045(13)70501-1_bib2 article-title: State-of-the-art therapeutics: Hodgkin's lymphoma publication-title: J Clin Oncol doi: 10.1200/JCO.2005.05.016 – volume: 25 start-page: 579 year: 2007 ident: 10.1016/S1470-2045(13)70501-1_bib13 article-title: Revised response criteria for malignant lymphoma publication-title: J Clin Oncol doi: 10.1200/JCO.2006.09.2403 – volume: 96 start-page: 1692 year: 2011 ident: 10.1016/S1470-2045(13)70501-1_bib1 article-title: Management of fertility in patients treated for Hodgkin's lymphoma publication-title: Haematologica doi: 10.3324/haematol.2011.045856 – volume: 27 start-page: 805 year: 2009 ident: 10.1016/S1470-2045(13)70501-1_bib5 article-title: ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial publication-title: J Clin Oncol doi: 10.1200/JCO.2008.17.0910 – volume: 23 start-page: 9198 year: 2005 ident: 10.1016/S1470-2045(13)70501-1_bib18 article-title: ABVD versus modified Stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi publication-title: J Clin Oncol doi: 10.1200/JCO.2005.02.907 – volume: 25 start-page: 3902 year: 2007 ident: 10.1016/S1470-2045(13)70501-1_bib19 article-title: Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin's Disease publication-title: J Clin Oncol doi: 10.1200/JCO.2007.11.9867 – volume: 54 start-page: 683 year: 2013 ident: 10.1016/S1470-2045(13)70501-1_bib15 article-title: International validation study for interim PET in ABVD-treated, advanced-stage Hodgkin lymphoma: interpretation criteria and concordance rate among reviewers publication-title: J Nucl Med doi: 10.2967/jnumed.112.110890 – volume: 359 start-page: 2065 year: 2002 ident: 10.1016/S1470-2045(13)70501-1_bib20 article-title: Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial publication-title: Lancet doi: 10.1016/S0140-6736(02)08938-9 – volume: 109 start-page: 905 year: 2007 ident: 10.1016/S1470-2045(13)70501-1_bib23 article-title: Risk adapted BEACOPP regimen can reduce the cumulative dose chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome publication-title: Blood doi: 10.1182/blood-2006-04-019901 – volume: 365 start-page: 203 year: 2011 ident: 10.1016/S1470-2045(13)70501-1_bib7 article-title: ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned publication-title: N Engl J Med doi: 10.1056/NEJMoa1100340 – volume: 22 start-page: 1532 year: 2004 ident: 10.1016/S1470-2045(13)70501-1_bib17 article-title: How important is bleomycin in the adriamycin + bleomycin + vinblastine + dacarbazine regimen? publication-title: J Clin Oncol doi: 10.1200/JCO.2004.99.010 – reference: 24815777 - Immunotherapy. 2014;6(4):371-5 – reference: 24239219 - Lancet Oncol. 2013 Dec;14(13):1254-6 |
| SSID | ssj0017105 |
| Score | 2.5432723 |
| Snippet | Roughly 70–80% of patients with advanced stage Hodgkin's lymphoma are cured with various first-line and second-line treatments, including ABVD, BEACOPP, and... Summary Background Roughly 70–80% of patients with advanced stage Hodgkin's lymphoma are cured with various first-line and second-line treatments, including... Roughly 70-80% of patients with advanced stage Hodgkin's lymphoma are cured with various first-line and second-line treatments, including ABVD, BEACOPP, and... Summary Background: Roughly 70-80% of patients with advanced stage Hodgkin's lymphoma are cured with various first-line and second-line treatments, including... Background Roughly 70-80% of patients with advanced stage Hodgkin's lymphoma are cured with various first-line and second-line treatments, including ABVD,... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1348 |
| SubjectTerms | Adult Aged Anemia - chemically induced Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bleomycin - administration & dosage Bleomycin - adverse effects Brentuximab Vedotin Chemotherapy Dacarbazine - administration & dosage Dacarbazine - adverse effects Disease prevention Dose-Response Relationship, Drug Doxorubicin - administration & dosage Doxorubicin - adverse effects Drug Administration Schedule Drug dosages Female Hematology Hematology, Oncology and Palliative Medicine Hodgkin Disease - diagnosis Hodgkin Disease - drug therapy Humans Immunoconjugates - administration & dosage Immunoconjugates - adverse effects Infusions, Intravenous Kaplan-Meier Estimate Lymphoma Male Middle Aged Neutropenia Neutropenia - chemically induced Peripheral neuropathy Radiation therapy Toxicity Treatment Outcome Vinblastine - administration & dosage Vinblastine - adverse effects |
| Title | Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S1470204513705011 https://www.clinicalkey.es/playcontent/1-s2.0-S1470204513705011 https://dx.doi.org/10.1016/S1470-2045(13)70501-1 https://www.ncbi.nlm.nih.gov/pubmed/24239220 https://www.proquest.com/docview/1464953520 https://www.proquest.com/docview/1462188046 https://www.proquest.com/docview/1751213191 https://www.proquest.com/docview/1751227832 |
| Volume | 14 |
| WOSCitedRecordID | wos000327539600047&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1474-5488 dateEnd: 20251013 omitProxy: false ssIdentifier: ssj0017105 issn: 1470-2045 databaseCode: 7X7 dateStart: 20000901 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Nursing & Allied Health Database customDbUrl: eissn: 1474-5488 dateEnd: 20251013 omitProxy: false ssIdentifier: ssj0017105 issn: 1470-2045 databaseCode: 7RV dateStart: 20000901 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1474-5488 dateEnd: 20251013 omitProxy: false ssIdentifier: ssj0017105 issn: 1470-2045 databaseCode: BENPR dateStart: 20000901 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database (ProQuest) customDbUrl: eissn: 1474-5488 dateEnd: 20251013 omitProxy: false ssIdentifier: ssj0017105 issn: 1470-2045 databaseCode: 8C1 dateStart: 20000901 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwELdgQ4gXvj8KYzISEiAtzE7sOOYFtWPTHqCaBkx9sxzbgYouKU07sf-CP5mz87EXtiLx4kqNf3IUn-9-Z5_vEHoJDFtIaW1EHOURWHwdSQ0-D1gfVkgmgJOHi8IfxXicTSbyqN1wq9uwyk4nBkVtK-P3yHdhRftQSB6T9_Ofka8a5U9X2xIa19Em9dwY5Fkcn_SnCKIJYaRMkMinXb-4wbP7uf_zNU3eCMLBq6aX2abLuGewQQd3_vft76LbLfvEw0Zc7qFrrryPbn5qz9cfoN8jn6xp9Wt6qnN85sBjnZYYRgD32Vns92zxcHTyAVcLPIQfILy4TcxaN0-BpM_OsW3i9wByWNlvP6blqxrPzkFuqlP9Dms8_w62E9Md7Gt3RSCHbraDLQAiV4PMBGHBIfHtQ_T1YP_L3mHU1myIDE-zJbijWkhuKHEZsQa0esIEt4Zbp1NRGBrTIs0k0zxxvBBWgK3kheSE5ZkxppDJI7RRVqV7gnBqnRQFTa12jlHDcp4XxPA451nOUpoPEOtmS5k2obmvqzFTfeSan2TlJ1nRRIVJVnSA3vaweZPRYx0g7URBdddVQcEqsDnrgOJvQFe3aqJWVNWxIg3ag2kSoIDMemTLhBqG8y-DbnUSqC7G6cVvgF70j0GR-NMhXbpqFfrEPjkfS6_oI7hPAQg-_po-vn5LPECPm9XSf2dP3mUck6dXv-QzdCv2VUdC1NAW2lguVu45umHOltN6sR3WuG8nIrQZtNke3Uabo_3x0fEfGeVWEQ |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFLamgYAX7ozCACOBAGnZYseOYySEOsbUaV2FxIb6ZhLbgYouKU076L_gl_AbOc5tL2zlZQ88RYr9KYlzrsnxdxB6BhG2kNIYz7eEe-DxY0_GkPOA92GpZAJi8nKjcF8MBtFwKD-soN_NXhhXVtnYxNJQm1y7b-RboNGuFJJT_-3ku-e6Rrm_q00LjUos9u3iB6RsxZu9HXi_zyndfX_4rufVXQU8zcNoBglTLCTXxLeRbzTYnYAJbjQ3Ng5FqgklaRhJFvPA8lQYAdacp5L7LIm01qkjXwKTfwnsuHDJnhi2CR4RVckkYcL3HM376Y6hrY_tyZckeCV8Dlk8OcsXnhXrlj5v98b_tlo30fU6usbdSh1uoRWb3UZXDur6gTvo17Yjo5r_HB3HCT6xkJGPMgxPlMCowe6bNO5uf9rB-RR34QABPa6JZ4tqFJKQ8QKbqj4RIL3cfPk2yl4UeLwAvciP49c4xpOvEBtgsoFdbzIP9MyON7ABgGcL0IlSGXBJ7HsXHV3IetxDq1me2fsIh8ZKkZLQxNYyolnCk9TXnCY8SlhIkg5ijXQoXRO2u74hY9VW5jmhUk6oFAlUKVSKdNBmC5tUjCXLAGEjeqrZjgsORIFPXQYUfwPaojaDhSKqoMqv0A5MghIKyKhF1pFeFcH9y0XXG4lXp9dpxb2DnrbDYCjd3684s_m8nEMd-SALz5kjuKM4JJIsmeP609AOWqu0s11nl5xISv0H59_kE3S1d3jQV_29wf5DdI26DitlhdQ6Wp1N5_YRuqxPZqNi-ri0Lxh9vmgV_QO2p6_J |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFLamgSZexp0VBhgJBEgLjR07jpEQ6laqTRvVJBjam0lsByq6pDTtoP-C38Ov4zi3vbCVlz3wFCn2pyTOuSafz0HoKUTYQkpjPN8S7oHHjz0ZQ84D3oelkgmIycuNwgdiOIyOj-XhCvrd7IVxtMrGJpaG2uTafSPvgkY7KiSnfjetaRGH_cHbyXfPdZByf1qbdhqViOzbxQ9I34o3e314188oHbz7uLPr1R0GPM3DaAbJUywk18S3kW802KCACW40NzYORaoJJWkYSRbzwPJUGAGWnaeS-yyJtNapK8QE5v-KCMLAJX7RTksvIaKiTxImfM-VfD_bPdT90J58QYKXwueQ0ZPz_OJ5cW_p_wbX_-eVu4HW66gb9yo1uYlWbHYLrb2veQW30a9tV6Rq_nN0Eif41EKmPsowPF0Cowa7b9W4t_2pj_Mp7sEBAn1cF6QtqlFITsYLbCreIkB2c_Pl2yh7XuDxAvQlP4lf4xhPvkLMgMkWdj3LPNA_O97CBgCeLUBXSiXBZcHfO-joUtbjLlrN8sxuIBwaK0VKQhNby4hmCU9SX3Oa8ChhIUk6iDWSonRdyN31ExmrlrHnBEw5AVMkUKWAKdJBr1rYpKpksgwQNmKomm264FgU-NplQPE3oC1q81googqq_ArtwCQooYCMWmQdAVaR3b9cdLORfnV2nVb0O-hJOwwG1P0VizObz8s51BUlZOEFcwR3pQ-JJEvmuL41tIPuVZrarrNLWiSl_v2Lb_IxWgPNVAd7w_0H6Bp1jVdK4tQmWp1N5_YhuqpPZ6Ni-qg0NRh9vmwN_QNI1rhQ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Brentuximab+vedotin+combined+with+ABVD+or+AVD+for+patients+with+newly+diagnosed+Hodgkin%27s+lymphoma%3A+a+phase+1%2C+open-label%2C+dose-escalation+study&rft.jtitle=The+lancet+oncology&rft.au=Younes%2C+Anas&rft.au=Connors%2C+Joseph+M&rft.au=Park%2C+Steven+I&rft.au=Fanale%2C+Michelle&rft.date=2013-12-01&rft.issn=1474-5488&rft.eissn=1474-5488&rft.volume=14&rft.issue=13&rft.spage=1348&rft_id=info:doi/10.1016%2FS1470-2045%2813%2970501-1&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_m | http://cvtisr.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F14702045%2FS1470204513X7158X%2Fcov150h.gif |